Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Immunofluorescence

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43925   clinical trials with a EudraCT protocol, of which   7306   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    102 result(s) found for: Immunofluorescence. Displaying page 1 of 6.
    1  2  3  4  5  6  Next»
    EudraCT Number: 2016-002790-35 Sponsor Protocol Number: C12-48 Start Date*: 2019-02-07
    Sponsor Name:INSERM
    Full Title: Phase I/II ex vivo gene therapy clinical trial for RDEB using autologous skin equivalent grafts genetically corrected with a COL7A1-encoding SIN retroviral vector
    Medical condition: The trial aims to treat the recessive dystrophic epidermolysis bullosa (RDEB) by grafting one to three subjects with RDEB with autologous COL7A1-modified skin equivalents, using SIN-RV encoding COL...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10074980 Epidermolysis bullosa aquisita LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-000287-32 Sponsor Protocol Number: D325AC00002 Start Date*: 2020-12-02
    Sponsor Name:AstraZeneca AB
    Full Title: A Multinational, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Investigate the Use of Benralizumab as a Treatment Option for Patients with Bullous Pemphigoid (FJORD)
    Medical condition: Bullous Pemphigoid
    Disease: Version SOC Term Classification Code Term Level
    21.1 10040785 - Skin and subcutaneous tissue disorders 10006567 Bullous pemphigoid LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Prematurely Ended) DE (Prematurely Ended) FR (Ongoing) IT (Prematurely Ended) GR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-001859-35 Sponsor Protocol Number: cro632 Start Date*: 2007-04-13
    Sponsor Name:Imperial College London
    Full Title: Abatacept in ANCA associated vasculitis: ABAVAS
    Medical condition: Anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis
    Disease: Version SOC Term Classification Code Term Level
    8.1 10050894 Anti-neutrophil cytoplasmic antibody positive vasculitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) DE (Prematurely Ended) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-004930-27 Sponsor Protocol Number: MTOR-INHIBITION-SARCOIDOSIS Start Date*: 2019-02-05
    Sponsor Name:Medical University of Vienna
    Full Title: Systems medicine analysis of sarcoidosis by targeting mTOR in a pilot study of sirolimus as treatment in patients with sarcoidosis
    Medical condition: Sarcoidosis with cutaneous affections
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-005987-67 Sponsor Protocol Number: AK802 Start Date*: 2021-12-22
    Sponsor Name:Akari Therapeutics Plc
    Full Title: A randomized, part A partial blinded and part B double blinded, placebo-controlled 24-week clinical study to evaluate the efficacy and safety of nomacopan therapy in adult patients with bullous pem...
    Medical condition: moderate to severe bullous pemphigoid
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10006567 Bullous pemphigoid LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing) NL (Ongoing)
    Trial results: View results
    EudraCT Number: 2021-000077-83 Sponsor Protocol Number: SRP-9001-101 Start Date*: 2022-11-10
    Sponsor Name:Sarepta Therapeutics, Inc.
    Full Title: Systemic gene delivery Phase I/IIa clinical trial for Duchenne muscular dystrophy using rAAVrh74.MHCK7.micro-dystrophin (microDys-IV-001)
    Medical condition: Duchenne Muscular Dystrophy
    Disease: Version SOC Term Classification Code Term Level
    20.1 10010331 - Congenital, familial and genetic disorders 10052655 Duchenne muscular dystrophy gene carrier PT
    Population Age: Children, Under 18 Gender: Male
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2005-002391-14 Sponsor Protocol Number: SAWV1003 Start Date*: 2005-09-29
    Sponsor Name:Moorfields Eye Hospital NHS Foundation Trust
    Full Title: Pulsed Intravenous Methylprednisolone for Ocular Pemphigoid- A Pilot Study
    Medical condition: ocular mucous membrane pemphigoid
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2022-001780-27 Sponsor Protocol Number: HTA-HG5-04 Start Date*: Information not available in EudraCT
    Sponsor Name:Holostem Terapie Avanzate s.r.l.
    Full Title: OPEN-LABEL, UNCONTROLLED, CLINICAL TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF AUTOLOGOUS FIBRIN-CULTURED EPIDERMAL GRAFTS CONTAINING EPIDERMAL STEM CELLS GENETICALLY MODIFIED FOR RESTORATION OF E...
    Medical condition: Inherited Epidermolysis Bullosa (EB) is a group of rare, devastating genetic disorders characterized by structural and mechanical fragility of skin and mucosal membranes, impairing the patient’s qu...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10014989 Epidermolysis bullosa PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-000756-42 Sponsor Protocol Number: MEX0111 Start Date*: Information not available in EudraCT
    Sponsor Name:Dompé s.p.a.
    Full Title: A phase 2, multicentre, single arm, pilot study to assess the efficacy and the safety of 150 mg twice a day oral DF2156A in patients with active bullous pemphigoid.
    Medical condition: active bullous pemphigoid
    Disease: Version SOC Term Classification Code Term Level
    14.0 10040785 - Skin and subcutaneous tissue disorders 10006567 Bullous pemphigoid LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-002333-40 Sponsor Protocol Number: ARGX-113-1701 Start Date*: 2018-01-31
    Sponsor Name:argenx BVBA
    Full Title: An Open-label, Non-controlled, Phase II Study to Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, Efficacy and Conditions of Use of ARGX-113 in Patients with Mild to Moderate Pemphigus (Vul...
    Medical condition: Pemphigus (Vulgaris or Foliaceus)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10052802 Pemphigus vulgaris LLT
    20.0 100000004858 10057069 Pemphigus foliaceus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) IT (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2005-003610-15 Sponsor Protocol Number: RITUXVAS Start Date*: 2005-12-15
    Sponsor Name:Cambridge University Hospitals NHS Foundation Trust
    Full Title: An international, randomised, open trial comparing a rituximab based regimen with a standard cyclophosphamide/azathioprine regimen in the treatment of 'generalised' ANCA associated vasculitis.
    Medical condition: Anti neutophil cytoplasmic antibody (ANCA) associated vasculitis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) CZ (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2008-000793-20 Sponsor Protocol Number: PNS2008-01 Start Date*: 2008-05-05
    Sponsor Name:Erasmus MC [...]
    1. Erasmus MC
    2.
    Full Title: Sirolimus (Rapamune®) for the treatment of anti-Hu associated paraneoplastic neurological syndromes
    Medical condition: Paraneoplastic Neurological Syndromes associated with anti-Hu antibodies
    Disease: Version SOC Term Classification Code Term Level
    9.1 10014619 Encephalomyelitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-002836-18 Sponsor Protocol Number: AK801 Start Date*: 2018-05-07
    Sponsor Name:Akari Therapeutics Plc.
    Full Title: A Phase IIa open label single arm study of safety and efficacy of rVA576 in adult mild to moderate Bullous Pemphigoid subjects
    Medical condition: Mild to Moderate Bullous Pemphigoid
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10006567 Bullous pemphigoid LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-004361-32 Sponsor Protocol Number: KKS-166 Start Date*: 2013-02-26
    Sponsor Name:Philipps-Universität Marburg
    Full Title: Effect of simvastatin in combination with a superpotent topical corticosteroid in bullous pemphigoid A prospective multi-centre randomised double-blind placebo-controlled pilot study
    Medical condition: Bullous pemphigoid (BP) is the most frequent blistering autoimmune disease of the skin. The disease itself is characterized by the development of bullous lesions, frequently following a prodromal p...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-000605-72 Sponsor Protocol Number: CB+MSCforEB Start Date*: 2014-02-06
    Sponsor Name:Universitair Medisch Centrum Utrecht
    Full Title: Unrelated cord blood transplantation after reduced toxicity conditioning with mesenchymal stromal cell co-infusion in patients with severe epidermolysis bullosa
    Medical condition: The source population consists of patients referred to or within the UMC Groningen because they have diagnosed clinically and genetically severe generalized RDEB.
    Disease:
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-004884-19 Sponsor Protocol Number: LENTICOL-F Start Date*: 2016-05-24
    Sponsor Name:King's College London [...]
    1. King's College London
    2. Guy's and St Thomas' NHS Foundation Trust
    Full Title: Phase I study of lentiviral-mediated COL7A1 gene-modified autologous fibroblasts in adults with recessive dystrophic epidermolysis bullosa (RDEB)
    Medical condition: Recessive Dystrophic Epidermolysis Bullosa
    Disease: Version SOC Term Classification Code Term Level
    18.1 10010331 - Congenital, familial and genetic disorders 10014989 Epidermolysis bullosa PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-000171-36 Sponsor Protocol Number: C20-54 Start Date*: 2021-03-23
    Sponsor Name:INSERM
    Full Title: PHASE I-II EFFICACY-TOXICITY OF ARTESUNATE IN FRIEDREICH ATAXIA
    Medical condition: Friedreich Ataxia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10017374 Friedreich's ataxia PT
    Population Age: Adolescents, Under 18, Adults Gender: Male
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-000261-36 Sponsor Protocol Number: HTA-HG5-02 Start Date*: 2021-09-07
    Sponsor Name:HOLOSTEM TERAPIE AVANZATE S.R.L.
    Full Title: MULTICENTRE, OPEN-LABEL, UNCONTROLLED, PIVOTAL CLINICAL TRIAL TO CONFIRM THE EFFICACY AND SAFETY OF AUTOLOGOUS FIBRIN-CULTURED EPIDERMAL GRAFTS CONTAINING EPIDERMAL STEM CELLS GENETICALLY MODIFIED ...
    Medical condition: Inherited Epidermolysis Bullosa (EB) is a group of rare, devastating genetic disorders characterized by structural and mechanical fragility of skin and mucosal membranes, impairing the patient's qu...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10014989 Epidermolysis bullosa PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-002439-14 Sponsor Protocol Number: SHP640-301 Start Date*: Information not available in EudraCT
    Sponsor Name:Shire Human Genetic Therapies, Inc.
    Full Title: A Phase 3, Multi-center, Randomized, Double-Masked Study to Evaluate the Clinical Efficacy and Safety of SHP640 (PVP-Iodine 0.6% and Dexamethasone 0.1%) Ophthalmic Suspension Compared to PVP-Iodine...
    Medical condition: Adenoviral Conjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10001257 Adenoviral conjunctivitis PT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) EE (Prematurely Ended) HU (Prematurely Ended) GB (Prematurely Ended) ES (Prematurely Ended) PL (Prematurely Ended) AT (Prematurely Ended) FR (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-002330-38 Sponsor Protocol Number: RituxiCAN-C4 Start Date*: 2006-11-22
    Sponsor Name:King's College London
    Full Title: Randomised Trial of Anti-CD20 in C4d+ Chronic Allograft Nephropathy
    Medical condition: Renal Transplant Rejection - chronic
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021428 - Immune system disorders 10023439 Kidney transplant rejection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Jun 17 19:34:25 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA